Prognostic implications of morphology and karyotype in primary XXXX .

@entity1 @entity2214 @entity7139 @entity417 @entity6130 @entity2590 @entity3052 @entity2008
Forty-nine @entity1 with primary @entity2590 ( @entity2590 ) were subclassified according to French-American-British (FAB) Cooperative Group criteria. Eight @entity1 had acquired @entity417 (AISA), ten had @entity6130 ( @entity6130 ), 14 had @entity417 ( @entity417 ), nine had @entity7139 ( @entity7139 ), and five had @entity7139 ( @entity7139 ); three @entity1 could not be subclassified. The actuarial median survival for @entity1 with AISA or with @entity417 had not been reached at 60 months of follow-up. The median survival times for @entity1 with @entity6130 , @entity7139 , and @entity7139 were 25, 21, and 16 months, respectively. The percentages of @entity1 with each subtype who developed @entity3052 were none in AISA, 20% in @entity6130 , 7% in @entity417 , 56% in @entity7139 , and 40% in @entity7139 . @entity1 with @entity6130 had a poor prognosis independent of transformation to @entity3052 ( @entity3052 ), whereas @entity1 with @entity7139 and @entity7139 had a high incidence of transformation and short survival times. @entity2008 were present in bone marrow cells from 19 @entity1 at the time of diagnosis, and two others developed an abnormal karyotype at the time of leukemic transformation. The most frequent abnormalities, including initial and evolutionary changes, were trisomy 8 (9 @entity1 ), deletion of 5q (4 @entity1 ), and deletion of 20q (4 @entity1 ). The median survival times were 32 months for @entity1 with an abnormal karyotype, and 48 months for those with a normal karyotype (P = 0.2). Specific @entity2008 were not associated with particular histologic subtypes; however, a high percentage of @entity1 with @entity7139 and @entity7139 had an abnormal clone (89% and 80%, respectively). The percentages of @entity1 with @entity2214 were 13% for AISA, 20% for @entity6130 , and 29% for @entity417 . The @entity2590 transformed to @entity3052 in 42% of @entity1 with an abnormal karyotype, compared to 10% of those with an initially normal karyotype (P less than .01). Among @entity1 with @entity417 , @entity7139 , and @entity7139 , the risk of leukemic transformation was confined to those with an abnormal karyotype (P less than .01). Thus, in the present study, morphology and karyotype combined were the best indicators of outcome in @entity1 with @entity2590 .
